1. known hypersensitivity or allergy to any of the study products to be administered. 2. participation in any other investigational device or drug study within 30 days preceding study screening visit. 3. treatment with calcium dobesilate or related molecules (e.g., ethamsylate) within 30 days preceding screening visit, or current treatment with any other investigational agent(s). 4. breastfeeding, unless if the patient agrees to stop breastfeeding 5. treatment with any investigational, emergency use authorization-approved, or approved drug for covid-19, such as, but not limited to: monoclonal antibody treatment, direct or indirect antiviral treatment, and others according to local guidelines. 6. any kind of disorder or medical conditions that, in the opinion of the investigators, may be associated with increased risk to the participant, may affect patients' compliance, or may interfere with study assessments or outcomes. 7. inability to follow and comply with study procedures. 8. participant has hospitalization criteria according to local guidelines (sat \< 95%, rr \>25) at the time of screening or is admitted to hospital prior to randomization 9. participant is, in the opinion of the investigators, likely to deteriorate in the next 24-48h and require hospitalization

1. known hypersensitivity or allergy to any of the study products to be administered. 2. participation in any other investigational device or drug study within 30 days preceding study screening visit. 3. treatment with calcium dobesilate or related molecules (e.g., ethamsylate) within 30 days preceding screening visit, or current treatment with any other investigational agent(s). 4. breastfeeding, unless if the patient agrees to stop breastfeeding 5. treatment with any investigational, emergency use authorization-approved, or approved drug for covid-19, such as, but not limited to: monoclonal antibody treatment, direct or indirect antiviral treatment, and others according to local guidelines. 6. any kind of disorder or medical conditions that, in the opinion of the investigators, may be associated with increased risk to the participant, may affect patients' compliance, or may interfere with study assessments or outcomes. 7. inability to follow and comply with study procedures. 8. participant has hospitalization criteria according to local guidelines (sat \< 95%, rr \>25) at the time of screening or is admitted to hospital prior to randomization 9. participant is, in the opinion of the investigators, likely to deteriorate in the next 24-48h and require hospitalization

known hypersensitivity or allergy to any of the study products to be administered. participation in any other investigational device or drug study within 30 days preceding study screening visit. treatment with calcium dobesilate or related molecules (e.g., ethamsylate) within 30 days preceding screening visit, or current treatment with any other investigational agent(s). breastfeeding, unless if the patient agrees to stop breastfeeding treatment with any investigational, emergency use authorization-approved, or approved drug for covid-19, such as, but not limited to: monoclonal antibody treatment, direct or indirect antiviral treatment, and others according to local guidelines. any kind of disorder or medical conditions that, in the opinion of the investigators, may be associated with increased risk to the participant, may affect patients' compliance, or may interfere with study assessments or outcomes. inability to follow and comply with study procedures. participant has hospitalization criteria according to local guidelines (sat < 95%, rr >25) at the time of screening or is admitted to hospital prior to randomization participant is, in the opinion of the investigators, likely to deteriorate in the next 24-48h and require hospitalization

known hypersensitivity or allergy to any of the study products to be administered. participation in any other investigational device or drug study within 30 days preceding study screening visit. treatment with calcium dobesilate or related molecules (e.g., ethamsylate) within 30 days preceding screening visit, or current treatment with any other investigational agent(s). breastfeeding, unless if the patient agrees to stop breastfeeding treatment with any investigational, emergency use authorization-approved, or approved drug for covid-19, such as, but not limited to: monoclonal antibody treatment, direct or indirect antiviral treatment, and others according to local guidelines. any kind of disorder or medical conditions that, in the opinion of the investigators, may be associated with increased risk to the participant, may affect patients' compliance, or may interfere with study assessments or outcomes. inability to follow and comply with study procedures. participant has hospitalization criteria according to local guidelines (sat < 95%, rr >25) at the time of screening or is admitted to hospital prior to randomization participant is, in the opinion of the investigators, likely to deteriorate in the next 24-48h and require hospitalization